Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSAS (obstructive sleep apnoea syndrome) therapy cuts cardiovascular events:

This article was originally published in Clinica

Executive Summary

Treating obstructive sleep apnoea syndrome (OSAS) in patients with coronary artery disease (CAD) could significantly reduce their chances of suffering from cardiovascular events. Olivier Milleron, of the Hopital Ambroise Pare, Boulogne, France, and colleagues compared the outcomes of 54 CAD patients - 25 of who received either continuous positive airway pressure therapy or surgery for OSAS, and 29 patients who were left untreated. A composite incidence of cardiovascular deaths, ischaemic events and cardiovascular hospitalisations was observed in just 24% of the treatment group versus 58% of non-treatment group, the researchers reported at the recent American College of Cardiology meeting in Chicago.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel